Cross-Sectional LENS Analysis Ties Low-Level Nighttime Light to 55-Minute Sleep Loss in Schizophrenia Outpatients

The LENS study used seven-day wrist actigraphy plus bedside photometer readings to quantify illuminance and sleep parameters in stable outpatients. Median exposure reached only 1.4 lux by actigraphy and 4.1 lux by photometer, yet dose-response associations persisted after controlling for age, BMI, symptoms, medications, daytime light, and day length. Objective deficits were clear; Pittsburgh Sleep Quality Index scores showed no parallel relationship, highlighting a possible dissociation between measured and perceived sleep.

Prior observational work in bipolar disorder and major depression has linked even sub-5-lux bedroom light to delayed melatonin onset and reduced slow-wave sleep, yet schizophrenia cohorts have been understudied. The present findings extend that pattern while underscoring that cross-sectional data cannot separate whether light disrupts sleep or whether patients with poorer sleep keep lights on. Blue-light wavelength effects further suggest melanopsin-mediated pathways may be relevant.

Reducing ambient light remains a low-cost target, but residential and hospital lighting standards still prioritize safety over circadian considerations. Future work must test whether darkening bedrooms below 1 lux for four weeks improves both actigraphic sleep and next-day functioning before guidelines change.

Intervention trials are now required to establish temporality and clinical benefit.